Type-A c-aminobutyric acid receptors (GABA A Rs) are the principal mediators of rapid inhibitory synaptic transmission in the human brain. A decline in GABA A R signalling triggers hyperactive neurological disorders such as insomnia, anxiety and epilepsy. Here we present the first three-dimensional structure of a GABA A R, the human b3 homopentamer, at 3 Å resolution. This structure reveals architectural elements unique to eukaryotic Cys-loop receptors, explains the mechanistic consequences of multiple human disease mutations and shows an unexpected structural role for a conserved N-linked glycan. The receptor was crystallized bound to a previously unknown agonist, benzamidine, opening a new avenue for the rational design of GABA A R modulators. The channel region forms a closed gate at the base of the pore, representative of a desensitized state. These results offer new insights into the signalling mechanisms of pentameric ligand-gated ion channels and enhance current understanding of GABAergic neurotransmission.
In response to binding the neurotransmitter GABA, released at inhibitory synapses, GABA A R chloride channels open and depress neuronal excitability in the adult central nervous system 1 . GABA A Rs belong to a superfamily of pentameric ligand-gated ion channels (pLGICs) known as the Cys-loop receptors, which includes the cation-selective nicotinic acetylcholine receptors (nAChRs) and serotonin type 3 receptors (5HT 3 Rs), as well as anion-selective glycine receptors (GlyRs) 2 . These molecules assemble as pentamers from a variety of subunits. In human GABA A Rs these subunits are encoded by 19 different genes: a1-6, b1-3, c1-3, d, e, h, p and r1-3 (ref. 3) . Most physiological heteromeric formats are thought to include two a, two b and one other, most frequently a c subunit 4 . b3 subunits can also efficiently assemble into functional homomeric channels, and although they have yet to be identified as discrete populations in the brain, they serve as meaningful models for the heteromeric receptors 5 . Each subunit contributes an extracellular domain of 200-250 amino acids, an a-helical M1-M4 transmembrane bundle and an M3-M4 intracellular loop of 85-255 residues 6 . Neurotransmitter molecules bind at extracellular pockets between subunits to induce a conformational switch that crosses to the transmembrane region to open the ion channel 7 . GABA A Rs are the targets of a wide range of drugs including benzodiazepines 8 , used in the treatment of epilepsy, insomnia, anxiety and panic disorder, and the intravenous general anaesthetics propofol and etomidate 5, 9 . GABA A Rs also mediate alcohol inebriation 10 and are targets for endogenous modulators such as neurosteroids 11 .
In the absence of GABA A R structural information, insights relied on analogies with related proteins. The soluble acetylcholine binding protein (AChBP) provided the first high-resolution model for the extracellular region 12 . Ground-breaking electron microscopic studies gradually led to an atomic model (at 4 Å ) of a complete heteromeric nAChR from the Torpedo marmorata electric organ 13, 14 , and a general framework for molecular understanding of pLGICs. Subsequently, crystal structures of two bacterial homologues, ELIC 15 and GLIC 16 , as well as the first structure of an anion-selective Cys-loop receptor, the Caenorhabditis elegans glutamate-gated chloride channel a homopentamer (GluCla) 17 , were reported, providing insights into potential mechanisms of interaction with orthosteric ligands and allosteric modulators 17, 18 . Nevertheless, owing to limited sequence identities with GABA A R subunits, these models alone cannot adequately explain their rules of assembly, ligand binding and modulation, gating mechanism, or the consequences of numerous human mutations linked to epilepsy and insomnia. Aiming to address these unknowns, we report here the crystal structure of a human GABA A R, the b3 homopentamer.
Architecture of the GABA A R b3 homopentamer
Crystallization of human GABA A R b3 required truncation of the intracellular loop between transmembrane helices 3 and 4 (M3-M4). Residues from Gly 308 to Asn 421 were substituted by a linker sequence, SQPARAA 19 , to give the construct GABA A R-b3 cryst (residue numbering used here corresponds to the mature isoform 1, that is, Gln 26 in UniProt entry P28472 is Gln 1 in GABA A R-b3 cryst ). GABA A R-b3 cryst solubilized in detergent retained the ability to bind agonists (GABA and histamine), channel blockers (fipronil and picrotoxin) and the anaesthetic etomidate (Extended Data Fig. 1a-e ). Furthermore, in patch-clamped HEK293T cells expressing GABA A R-b3 cryst , application of the GABA A R b3 agonists histamine or propofol induced inward currents that were inhibited by the channel blockers fipronil and picrotoxin (Extended Data Fig. 1f, g) .
We crystallized and determined the structure of GABA A R-b3 cryst at 3 Å resolution (Extended Data Table 1 ). Viewed perpendicular to the central five-fold pseudo-symmetry axis, the receptor approximates a cylinder 110 Å in height, with diameter ranging from 60 to 80 Å ( Fig. 1a ), spanning the plasma membrane and protruding ,65 Å into the extracellular space. Viewed along the same pseudo-symmetry axis from the extracellular side, the pentamer has a toroidal (doughnut-like) profile, surrounded by 15 (three per subunit) N-linked glycans ( Fig. 1b ). Each extracellular domain (ECD) comprises an amino-terminal a-helix (a1) followed by ten b-strands folded into a curled b-sandwich, topologically similar to other family members characterized to date ( Fig. 1c and Extended Data Figs 2 and 3). A second a-helix (a2), between b-strands 3 and 4, is located under the a1 helix ( Fig. 1c ). Four additional helices (M1-M4) from each subunit come together to create the pentameric transmembrane domain (TMD), with M2 segments lining a pore that tapers as it traverses towards the intracellular side of the membrane ( Fig. 1b-d ). On the extracellular side, water and solutes access the pore from a vestibule surrounded by the ECDs and from lateral tunnels situated between the ECDs that are lined by an excess of negatively charged groups, suggesting putative cation modulation sites ( Fig. 1c , e and Extended Data Fig. 4a , d, g, h).
A positively charged ring halfway down the vestibule hosts putative anion binding sites at each inter-subunit interface (Extended Data Fig. 4d ), revealed by peaks (visible to an ,6s level) in F o -F c electron density maps calculated following refinement without anions modelled (Extended Data Fig. 5a ). Attempts to confirm the nature of these peaks by soaking heavy atom anions (for example, iodide) into the crystals and analysis of anomalous electron density maps were inconclusive. However, placement of chloride ions followed by refinement satisfactorily accounts for these electron density features (Extended Data Fig. 5a -c). This positively charged ring corresponds to the previously proposed ion selectivity filter in the vestibule of Cys-loop receptors 20 . Furthermore, these putative chloride sites are in spatial proximity (but structurally non-equivalent) to the 'anion site 1' reported in the bacterial channel GLIC 21 , and thus chloride ions might be important stabilizers of pLGIC assembly.
At the TMD level, two large non-overlapping pockets are located near residues previously inferred to bind the intravenous anaesthetics etomidate and propofol 5, 9 (Extended Data Fig. 6a -c). The putative propofolbinding pocket is structurally distinct from the one identified in the bacterial channel GLIC 18 . The binding and transduction modes of propofol on GABA A R-b3 cryst and GLIC are therefore unrelated, as are its relative potencies. Propofol potentiates and activates GABA A Rs but inhibits GLIC 5, 18 .
Determinants of assembly
The 19 different GABA A R subunits obey stringent rules for assembly specificity 4 , the molecular determinants of which are poorly understood. A comparison of inter-subunit interfaces from pLGIC structures available to date reveals considerable differences in the geometry and thermodynamics of complex formation, with GABA A R-b3 cryst subunits forming the most extensive, energetically favourable interactions (Extended Data Fig. 7b ). These occur in particular between ECDs, through patchworks of hydrogen bonds, salt bridges and van der Waals contacts (Fig. 2 a-c and Extended Data Fig. 7a-e ). Within the upper portions of the ECDs, between the a1 helices of adjacent subunits, the side chains of Arg 26 and Asp 17 form a salt-bridge network extending to Asp 24 and Lys 13 ( Fig. 2b) , an interaction specific to b-b and a-b subunits in human GABA A Rs (Extended Data Fig. 3 ). Between the a2 helices, the intersubunit interface is stabilized by a network of hydrogen bonds and salt bridges surrounding Arg 86, specific to the GABA A R b and GlyR subunits ( Fig. 2b and Extended Data Fig. 3 ). The loop connecting the a1 helix with the b1 strand also bridges this interface and mutations in it (or its proximity) are associated with childhood absence epilepsy and febrile seizures 22, 23 (Extended Data Fig. 3 ). The GABA A R b3 Gly7Arg mutation that excludes c2 subunits from heteromeric GABA A Rs 22 opposes and is likely to perturb the a1-b1 loop conformation (Fig. 2b) . The GABA A R c2 Arg43Gln mutation (equivalent to Arg28Gln in GABA A R-b3 cryst ), that also excludes c2 subunits 23 , resides within the a1-b1 loop and is predicted to disrupt its backbone organization ( Fig. 2b) .
Inter-subunit contacts between the central portions of ECDs involve the b4, b5, b59 and b6 strands and flanking loops. The b5-b59 loop is extended in GABA A R-b3 cryst and GluCla compared to nAChRs and AChBP (Extended Data Fig. 2d ), and protrudes into the neighbouring subunit ( Fig. 2c ). The b5-b59 loop His 107, strictly conserved in GABA A and Gly receptors, and main-chain amino groups in positions 104 and 108 coordinate putative chloride anions across this boundary (within the positively charged ring lining the vestibule discussed earlier; Fig. 2c parallel to the plasma membrane (a-helices red, except the pore-lining M2 shown in teal; b-strands blue; loops grey). N-linked glycans are shown in orange ball-and-stick representation. b, View from the extracellular space (synaptic cleft) down the five-fold pseudo-symmetry axis, with a single subunit coloured in grey. c, Two subunits, rainbow coloured from blue N terminus to red C terminus, illustrating secondary structure nomenclature.
A water-filled ECD vestibule and TMD pore shown in light green (diameter (W) indicated periodically) runs through the five-fold pseudo-symmetry axis of the pentamer, joined by lateral tunnels coming from between each of the subunit ECDs (only two shown for clarity, in grey). d, The pentameric transmembrane region, to illustrate the arrangement of helices M1-M4 and the M2-M3 loop (yellow). e, View of a lateral tunnel running between subunits into the central vestibule.
and Extended Data Fig. 5c ). Further interface contacts include a saltbridge network centred on Asp 101 and Arg 129, and a potential cation-p interaction between Lys 103 and Phe 105, both likely to influence assembly specificity based on residue conservation patterns ( Fig. 2c and Extended Data Fig. 3 ). Mutations within this ECD interface are linked to epileptic encephalopathies, for example Asn85Asp 24 , which will remodel interactions with basic residues adjoining the b5-b59 loop ( Fig. 2c ).
Neurotransmitter pocket and binding of a novel agonist
The neurotransmitter-binding pocket of GABA A Rs is located between ECDs. It comprises the b4 strand and adjacent residues (Asp 95-Leu 99), part of the b7-b8 loop (Glu 155-Tyr 159) and the b9-b10 loop (Phe 200-Tyr 205) from the 'principal' face, also known as loops A-C, respectively. The 'complementary' face in GABA A R-b3 cryst comprises a segment of the b2 strand (Tyr 62-Gln 64) and the b6 strand (Leu 125-Arg 129), also known as loops D and E, respectively, which come from equivalent motifs in a subunits in heteromeric GABA A Rs (Fig. 3a-c and Extended Data Fig. 3 ) 25 . The b9-b10 loop adopts a 'closed' conformation over the site, consistent with an agonist-bound conformation 17,26-28 (Extended Data Fig. 8 ). Closure is stabilized by salt bridges between the side chains of Arg 207, Glu 153 and Glu 155 (Fig. 3b, c) , residues previously implicated in GABA binding and channel activation [29] [30] [31] . Analogous interactions are required for ligand binding and activation of nAChRs 12, 32 .
We observed large positive peaks in the F o -F c electron density map in all five neurotransmitter-binding sites, which could be accounted for by benzamidine molecules, an additive that helped us obtain highresolution diffracting crystals (Extended Data Fig. 5d -f). To our knowledge, benzamidine or its derivatives have not been previously reported to act as GABA A R ligands. We recorded GABA A R-b3 cryst currents in HEK293S-GnTI 2 (deficient in N-acetylglucosaminyltransferase I activity) cells, and found benzamidine to behave as an agonist capable of inducing desensitization (half-maximal effective concentration (EC 50 ) 5 61 6 12 mM; n 5 4; Fig. 3d , e). Thermostabilization of GABA A R-b3 cryst in detergent micelles by benzamidine revealed a sensitivity similar to histamine (benzamidine EC 50 5 370 6 180 mM; histamine EC 50 5 400 6 150 mM; n 5 3; Fig. 3d and Extended Data Fig. 1c ). Classically, benzamidine is known as a highly potent serine-protease inhibitor, derivatives of which are in clinical trials for prevention of blood clotting 33 . However, given that GABA A R b3 agonists such as histamine act instead as potentiators of heteromeric GABA A Rs, characterization of benzamidine derivatives as positive modulators may offer new opportunities in drug development.
The benzamidine benzyl ring is stacked between the side chains of Phe 200 and Tyr 62, whereas its amidinium group forms hydrogen bonds with the Glu 155 side chain and backbone carbonyls of Ser 156 and Tyr 157, and putative cation-p interactions with the Tyr 157 and Tyr 205 aromatic rings (Fig. 3b , c). This binding mode is reminiscent of the principal face observed in GluCla and AChBP (Extended Data Fig. 8a, b ). Two epileptic encephalopathies are linked to mutations in this b3 subunit region, Asp95Asn and Glu155Gly 24 . Loss of Asp 95, which hydrogen bonds Ser 156 and Tyr 157, will probably destabilize the b7-b8 loop conformation, whereas Glu155Gly will impair binding of amino-groupcontaining ligands (Fig. 3b, c and Supplementary Discussion). 
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The impact of N-linked glycosylation Two of the three N-linked glycosylation sites present in each subunit (Asn 8, only visible in chain A, and Asn 80) are occupied by residual GlcNAc moieties following endoglycosidase F1 treatment. The third site, Asn 149 on the b7 strand ( Fig. 4 ), is conserved in almost all GABA A R b, nAChR and 5HT 3 R subunits (Extended Data Fig. 3 ) and was resistant to enzymatic digestion (Extended Data Fig. 5g -i). This glycan extends along the b9 and b10 strands that support the agonist-binding 'loop C', providing further contacts between these units and the b7 strand, which may facilitate the ECD-TMD signal transduction. Substitution of Asn 149 in GABA A R b2 reduces sensitivity to GABA 34 , and in GlyRs, Zn 21 coordination between the same three b-strands potentiates agonist sensitivity 35 . Furthermore, mutation of Arg 192 at the core of this network of glycan interactions is associated with chronic insomnia and increases the inactivation rate of GABA A Rs 36 . Importantly, the equivalent glycan in nAChR a1 also contacts the outer face of the ECD, and its enzymatic cleavage decreases nAChR function 37 .
Structural coupling between the ECD and TMD
For a neurotransmitter binding event to transmit to the channel gate, a signal must be transduced across the ECD-TMD interface. The inner and outer b-sheets of each GABA A R-b3 cryst ECD come together at the base through a conserved salt-bridge between b1-b2 loop Glu 52 and b10-strand Arg 216 (refs 14, 38) (Extended Data Fig. 7e ). Beneath this, in each subunit the ECD-TMD interface consists of two clusters of interactions: an array of polar contacts linking the outer portion of the M2-M3 loop with the b6-b7 ('Cys') loop (Fig. 5a) ; and van der Waals contacts between residues in the inner portion of the M2-M3 loop near the pore, the b1-b2 loop and the b6-b7 loop (Fig. 5b ). Central to both clusters is Pro 144 in the b6-b7 loop, conserved in all pLGICs (Extended Data Fig. 3 ) and adopting a cis conformation, which orients the neighbouring Tyr 143 backbone carbonyl downwards to engage in hydrogen bonds with M3 helix backbone amino groups (Fig. 5a ). These contacts ensure that the GABA A R-b3 cryst ECD-TMD interface is tightly structurally coupled, with a solvent-inaccessible surface area of 689 Å 2 , 100 Å 2 larger than observed in ELIC, but comparable to those observed in GluCla, GLIC, and the three nAChR structures solved in a membrane context by electron microscopy (Extended Data Fig. 9a ). Nevertheless, despite similarly strong interfaces, structural alignments of GABA A R-b3 cryst with other pLGICs reveal differences in their ECD-TMD relative orientations, where rotations within a ,20u range probably reflect the multiplicity of states (resting, activated and desensitized) that these receptors occupy 39 (Extended Data Fig. 9b-f ).
Mutations linked to epileptic encephalopathies highlight the importance of the ECD-TMD region 24, 40 . One such mutation, GABA A R b3 Tyr277Cys, will reduce hydrogen-bond connectivity between the M2-M3 loop and the b6-b7 loop and disrupt a stacking interaction with the Arg 141 guanidinium group (Fig. 5a ). Another mutation, GABA A R b1 Phe246Ser (Phe 221 in b3), is located at the top of M1 and will disrupt its interaction with the critical Tyr 143/Pro 144 motif at the apex of the b6-b7 loop (Fig. 5b) . A Lys289Met mutation reported in GABA A R c2 (Lys 274 in b3) affects a residue whose side chain, very well ordered in electron density maps, reaches across a neighbouring subunit ( Fig. 5b and Extended Data Fig. 7e ). This residue is conserved in GlyRs, for which mutations are linked to the rare human genetic startle disorder, hyperekplexia, and where detailed kinetic analysis of GlyR a1 Lys276Glu has revealed a significantly slower gating 41 . Thus, on the basis of the GABA A R-b3 cryst structure, it appears that this lysine facilitates the coordination of inter-subunit motions.
Channel structure and the desensitization mechanism
The GABA A R-b3 cryst pore is lined by five M2 helices ( Fig. 1a-d) , supporting 'rings' of residues between positions 259 and 209 (Fig. 6a ). In GABA A R-b3 cryst the M2 helices taper inwards from the 139 Thr 263 Boxed residue labels correspond to disease mutations discussed in main text.
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down to the intracellular border where the 229 Ala 248 side chains define the narrowest point, just 3.15 Å in diameter ( Fig. 6a, b ). This pore is too narrow to permit the passage of chloride anions (with a Pauling radius of 1.8 Å ) and therefore delineates a closed gate. However, this geometry fundamentally differs from closed structures reported to date, ELIC 15 and Torpedo nAChR 14 , which exhibit almost vertical M2 helices and have closed gates in the extracellular portion of the pore (99 up to 209) formed by bulky hydrophobic side chains (Fig. 6b ). In GABA A R-b3 cryst none of the M2 hydrophobic rings (19 Val, 39 Leu, 59 Ile, 89 Val, 99 Leu, 119 Met, 149 Ile and 189 Leu) line the pore. Instead, its trajectory more closely resembles the open conformations of GLIC 16 and GluCla 17 , which are narrowest at the intracellular border ( Fig. 6b and Extended Data Fig. 9g ).
The pore-lining residues in GABA A R-b3 cryst (Fig. 6a ) are generally in excellent agreement with those identified by cysteine accessibility studies in the GABA A R a1 subunit and by protonation of introduced charged residues in the open nAChR 42, 43 . However, the 99 Leu residues in GABA A R-b3 cryst (conserved across the mammalian Cys-loop receptors) are rotated out of the pore, with side chains placed between neighbouring M2 helices. This rotation is not observed in the open-to-closed M2 flexion motion in nAChR 44 . Irrespectively, the M2 rotation alone cannot explain the closed state of GABA A R-b3 cryst because superposition of each TMD individually onto the open GluCla equivalents, to remove its influence, reveals that the GABA A R-b3 cryst pore would still remain closed ( Fig. 6c-f) . Thus, the closed state of GABA A R-b3 cryst is principally accounted for by a unique conformation of its M2 helix ( Fig. 6a and Extended Data Fig. 9g ). The expanded extracellular portion of the pore in GABA A R-b3 cryst is stabilized by two rings of salt bridges. The first one involves 179 His 267 and 209 Glu 270 from adjacent M2 helices (Extended Data Fig. 7e ). His 267 lines both the pore and an inter-subunit cavity, coordinating Zn 21 for inhibition or propofol for potentiation 5, 45 (Extended Data Figs 6b, c and 7e) . The second ring is an intra-subunit interaction between the side chains of 199 Arg 269 and M3 Asp 282, which retracts M2 against M3 (Extended Data Fig. 7e ). This ring is conserved in GABA A R a-subunits and GlyR a-subunits, and substitutions of the equivalent 199 Arg 271 in GlyR a1 are the most frequent cause of hyperekplexia, with disease mutations Arg271Leu and Arg271Gln decoupling agonist binding from gating 46 .
The contracted intracellular portion of the pore is confined by the conformation of Tyr 299 side chains, which point towards the back of the M2 gate, compressing it shut (Fig. 6g) . Aromatic Phe or Tyr residues occupy this position across all human GABA A R and GlyR subtypes and in C. elegans GluCla (Extended Data Fig. 3) . Notably, however, in the GluCla open pore conformation the equivalent Phe 294 side chain is rotated upwards, preventing such compression (Fig. 6g ). During the gating process, conformation switching of side chains at this key position might account for local desensitization, and drugs that potentiate function by blocking desensitization [47] [48] [49] might do so by disabling this aromatic switch. A desensitized state of GABA A R-b3 cryst is in agreement with our electrophysiological recordings of benzamidine-induced desensitizing currents measured in HEK cells at saturating concentrations (10 mM), which approach those used in crystallization (33 mM; Fig. 3e ). Furthermore, in heteromeric GABA A Rs, swapping the b-subunit intracellular border with the equivalent nAChR a7 residues renders the receptor cation selective and ablates desensitization to GABA 50 .
Conclusion
Here we present the first X-ray structure of a GABA A R, the human b3 homopentamer, co-crystallized with a novel agonist, benzamidine. GABA A R-b3 cryst has a closed b9-b10 loop, being in an agonist-bound state, but the pore is shut, consistent with a desensitized conformation. To our knowledge, this is the first time when a pLGIC-desensitized state has been described crystallographically. These results shed new light on the conformational transitions that occur across pLGICs and provide a rational basis for understanding how multiple human disease mutations affect GABA A R assembly, glycosylation and agonist binding, as well as the signal transduction and gating processes. 
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METHODS SUMMARY
GABA A R-b3 cryst was expressed in HEK293S-GnTI 2 cells and immuno-affinity purified on Rho-1D4 antibody-coated beads that bind the carboxy-terminal 1D4 tag (TETSQVAPA). Pure GABA A R-b3 cryst was further isolated by size-exclusion chromatography and peak fractions were concentrated to 3 mg ml 21 . Crystallization was performed by sitting-drop vapour diffusion at 4 uC with a precipitating solution containing 11.5% PEG 4000, 100 mM NaCl, 100 mM Li 2 SO 4 , 100 mM N-(2-Acetamido)iminodiacetic acid buffer, pH 6.5, and 2% (v/w) benzamidine. Crystals were cryoprotected by soaking in precipitant solution supplemented with 20% glycerol. The GABA A R-b3 cryst X-ray structure was solved at 3 Å resolution, using the C. elegans glutamate-gated chloride channel a (GluCla 17 ) as a molecular replacement model. Phasing was followed by iterative rounds of manual model building and crystallographic refinement, leading to a complete model of the protein core. N-linked glycans, anions and benzamidine were subsequently added to the model and refined. Electrophysiological recordings were made from either transiently transfected HEK293T cells or HEK293S-GnTI 2 cells stably expressing GABA A R-b3 cryst .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
Construct design, optimization and small-scale screening. A synthetic complementary DNA construct encoding the full-length human GABA A R b3 subunit, based on GenBank accession number M82919, was codon-optimized for expression in mammalian cells. Approximately 100 construct variants were subsequently generated by PCR, to evaluate the consequences of N-linked glycosylation site removal, mutation of cysteine residues, N-terminal and C-terminal truncations, truncations in the intracellular loop connecting M3 and M4 and introduction of chimaeric domains (such as T4 lysozyme) into predicted flexible loops. These constructs were cloned into the pHLsec vector 51 , making use of the secretion signal sequence provided by the plasmid. To facilitate small-scale screening of protein expression, solubilization, purification and stabilization conditions, constructs were tagged N-terminally with monoVenus 52, 53 and C-terminally with a nine-amino-acid sequence derived from bovine rhodopsin (TETSQVAPA) that is recognized by the Rho-1D4 monoclonal antibody (University of British Columbia) 54, 55 . Small-scale expression trials were performed by transient transfection in adherent HEK293T cell cultures, as previously described 51 . Expression levels of recombinant GABA A R b3 variants were evaluated by western blotting using Rho-1D4 as a primary antibody and the efficiency of their cell surface trafficking was monitored by wide-field fluorescence microscopy. Suitable constructs underwent high-throughput solubilization screening by FSEC 56 , using a broad panel of detergents. For this and all subsequent steps, smallscale expression was performed in HEK293S-GnTI 2 cells, to reduce N-linked glycosylation heterogeneity 57, 58 . Cells were transiently transfected using Lipofectamine (Invitrogen) in an adherent format and 48-72 h later were re-suspended and solubilized in a 10 mM HEPES, pH 7.2, 300 mM NaCl buffer supplemented with a 1:100 (v/v) dilution of mammalian protease inhibitor solution (Sigma-Aldrich) and 1% detergent, for 2 h at 4 uC. Insoluble material was removed by centrifugation (10,000g, 15 min) and the supernatant incubated for 2 h at 4 uC with purified Rho-1D4 antibody coupled to CNBr-activated sepharose beads (GE Healthcare). Resin-bound samples were washed with 10 mM HEPES, pH 7.2, 300 mM NaCl buffer containing detergent at 33 CMC and receptor constructs were eluted overnight in the same buffer supplemented with 500 mM TETSQVAPA peptide (Genscript). For sizeexclusion chromatography (SEC), samples were loaded onto a Superdex 200 3.2/ 300 column (GE Healthcare) equilibrated in 10 mM HEPES, pH 7.2, 300 mM NaCl, 0.02% n-dodecyl-b-D-maltopyranoside (DDM, Anatrace), attached to a highperformance liquid chromatography system with automated micro-volume loader and in-line fluorescence detection (Shimadzu). Large-scale protein expression and purification. In preliminary large-scale expression trials, 6 l batches of HEK293S-GnTI 2 cells were grown in suspension to densities of 23 10 6 cells ml 21 in protein expression media (PEM, Invitrogen) supplemented with L-glutamine, non-essential amino-acids (Gibco) and 1% fetal calf serum (Sigma). For transient transfection, cells from 1 l cultures were collected by centrifugation (200g for 5 min) and re-suspended in 150 ml Freestyle medium (Invitrogen) containing 3 mg PEI Max (Polysciences) and 1 mg plasmid DNA, followed by a 3-6 h shaker-incubation. Subsequently, culture media were topped up to 1 l with PEM containing 4 mM valproic acid. Typically, 40-70% transfection efficiencies were achieved, as assessed by control transfections with a monoVenus-expressing plasmid 52, 53 . 48-72 h post-transfection cell pellets were collected, snap-frozen in liquid N2 and stored at 280 uC.
FSEC screening indicated that decyl maltose neopentyl glycol (DMNG, Anatrace) was the most suitable detergent for handling GABA A R b3 constructs, and that protein stability was enhanced by the addition of cholesterol hemisuccinate (CHS, Anatrace). Therefore, the solubilization buffer contained 10 mM HEPES, pH 7.2, 300 mM NaCl, 1% DMNG and 0.05% CHS. Proteins were affinity-purified on Rho-1D4 antibody-coupled beads as described above, concentrated by ultrafiltration to 1-2 mg ml 21 using 100-kDa cutoff membranes (Millipore) and applied to a Superdex 200 10/300 gel filtration column (GE Healthcare) equilibrated in 10 mM HEPES, pH 7.2, 150 mM NaCl, 0.007% (w/v) DMNG, 0.0006% (w/v) CHS. The GABA A R-b3 cryst construct. Residue numbers correspond to the Uniprot entry P28472. Throughout the manuscript, in agreement with the established customs within the ion channel community and to facilitate comparisons between our results and others', we adopted a numbering scheme whereby Gln 26 becomes Gln 1, as the first residue of the mature protein (after cleavage of the secretion signal sequence).
The most suitable construct in terms of yield and monodispersity spanned the full length of the mature GABA A R b3 isoform 1 (from Gln 26 to Asn 473) but with the intracellular M3-M4 loop (Gly 333-Asn 446) replaced with the short amino acid sequence SQPARAA 59, 60 . This is the construct we refer to as GABA A R-b3 cryst , because it eventually led to the crystal structure described in this manuscript. The N-terminal region is native (the N-terminal monoVenus tag was not present on the construct used for large-scale expression); however, we maintained the C-terminal TETSQVAPA tag for affinity purification.
Aiming to obtain the highest possible protein yields, a HEK293S-GnTI 2 cell line stably expressing GABA A R-b3 cryst was generated as described previously 61 . Pure protein yields from this cell line were typically ,0.02 mg g 21 cells (typically 10 g cells were obtained from 1 l culture), roughly twice that of transient transfection.
Crystallization and data collection. The homopentameric GABA A R-b3 cryst contains 15 N-linked glycosylation sites, bringing a considerable extra volume, flexibility and potential heterogeneity. Therefore, before crystallization, purified GABA A R-b3 cryst samples were concentrated to 3 mg ml 21 and incubated with 0.01 mg ml 21 endoglycosidase F1 (ref. 62) for 2 h at room temperature. Sitting drop vapour diffusion crystallization trials were performed in 96-well Greiner Crystal Quick X plates, using 200 nl protein plus 100 nl reservoir dispensed by a Cartesian Technologies robot 63 . Plates were maintained at 6.5 uC in a Formulatrix storage and imaging system. Initial crystals grew within 1-7 days in a range of conditions; however, they were poorly diffracting (no better than ,13 Å ). Subsequent rounds of optimization by additive screening 64 led to well-diffracting crystals (,3 Å ), grown in 11.5% PEG 4000, 100 mM NaCl, 100 mM Li 2 SO 4 , 100 mM N-(2-Acetamido)iminodiacetic acid, pH 6.5, 2% (w/v) benzamidine. Crystals were cryoprotected by soaking in reservoir solution supplemented with 20% glycerol, followed by flash-freezing in liquid nitrogen. Diffraction images of 0.2u oscillation were collected at the Diamond Light Source beamline I03, on a Pilatus 6M-F detector, and indexed, integrated and scaled using xia2 65 . Data collection statistics are shown in Extended Data Table 1 . Structure determination, refinement and analysis. The GABA A R-b3 cryst structure was solved by molecular replacement using the C. elegans glutamate-gated chloride channel a (GluCla 66 , PDB accession 3RHW) as a search model in Phaser 67 . An initial round of automated model building, structure refinement and density modification was performed using Phenix AutoBuild 68 followed by iterative steps of manual model building in Coot 69 and refinement in Buster 70 . During the refinement/building process it became clear that the N-terminal region (first nine residues) of one GABA A R-b3 cryst monomer (chain A) adopted a distinct, well-ordered conformation because of its involvement in crystal contacts. As a result, the strict five-fold non-crystallographic symmetry (NCS) restraints strategy was replaced at later stages by a local structural similarity restraints NCS approach, to allow pruning of genuine differences among matching chains from the NCS relation 71 . The final model contains one GABA A R-b3 cryst homopentamer per asymmetric unit. The complete polypeptide chains could be built, except for the C-terminal TETSQVAPA purification tag and the first nine N-terminal residues (QSVNDPGNM) in chains B, C, D and E. Furthermore, clear electron density is visible for benzamidine molecules, one of which occupies every orthosteric ligand binding site, as well as for 11 out of the 15 N-linked glycosylation sites, the remaining four being located in the N-terminal disordered regions of chains B-E. Glycans attached to Asn 149 in each chain were protected from endoglycosidase F1 cleavage owing to extensive interactions with the protein core, underlying their important structural role. Stereochemical properties of the model were assessed in Coot 69 and Molprobity 72 . Protein geometry analysis revealed no Ramachandran outliers, with 96.98% residues in favoured regions and 3.02% residues in allowed regions. Molprobity clash score after adding hydrogens is 5.74 (100th percentile) and the overall Molprobity score is 1.85 (100th percentile).
Sequence and structural alignments were performed in ClustalW 73 and SHP 74 , respectively. Protein interfaces were analysed using the PDBePISA web server at the European Bioinformatics Institute (http://www.ebi.ac.uk/pdbe/prot_int/pistart. html) 75 and residue conservation was mapped onto the crystal structure using ProtSkin 76 . Electrostatic surface potential calculations were performed using the APBS Tools plug-in in PyMOL 77 and pore/tunnel dimensions were analysed using the Caver 3.0 software for a probe radius of 1.4 Å (ref. 78) . Structural figures were prepared with the PyMOL Molecular Graphics System, Version 1.6, Schrödinger, LLC. Thermostability binding experiments. The thermostability of detergent-solubilized constructs was determined by heating them over a range of temperatures for equal time periods and then measuring the reduction in the intensity of the monodisperse SEC profile for each sample 79 . With increasing temperature, an increased proportion of protein is denatured, aggregates and therefore lost from the monodisperse peak when the protein is subsequently run on SEC. Protein stability was evaluated by plotting the decay in peak UV absorbance against increasing temperature, for example to obtain a 50% melting temperature (T m ). Purified GABA A R-b3 cryst protein at 0.05 mg ml 21 (20 nM) in 150 mM NaCl, 10 mM HEPES, pH 7.2, 0.007% DMNG (w/v), 0.0006% CHS (w/v) was separated into 50-ml aliquots in PCR tubes, and heated at a range of temperatures from 30-80 uC for 1 h. Samples were run on a high-performance liquid chromatography system with automated micro-volume loader (Shimadzu) through a Superdex 200 3.2/300 column (GE Healthcare) maintained in 300 mM NaCl, 10 mM HEPES, 0.007% DMNG (w/v), 0.0006% CHS (w/v). Monodisperse peak reduction with increasing temperature was measured relative to an unheated control sample maintained at 4 uC.
Importantly, because some drugs thermostabilize detergent-solubilized proteins upon binding 79 , the above thermostability assay also offers an efficient strategy to measure protein sensitivity to drugs in the detergent-containing environment, and RESEARCH ARTICLE
